Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng

Rhea-AI Filing Summary

Damora Therapeutics, Inc. filed an initial statement of beneficial ownership for Andrew Cheng. He is identified as a director of the company and this Form 3 establishes his status as a reporting person. The filing notes an attached Power of Attorney authorizing SEC reporting actions.

Key Terms

Form 3, reporting person, Power of Attorney

3 terms

Form 3 regulatory

"filed an initial statement of beneficial ownership for Andrew Cheng"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"establishes his status as a reporting person"

Power of Attorney regulatory

"The filing notes an attached Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

What does Damora Therapeutics (DMRA) report about Andrew Cheng in this Form 3?

The filing identifies Andrew Cheng as a director of Damora Therapeutics, Inc. and establishes him as a reporting person for SEC ownership disclosure purposes via this initial Form 3.

Does the Damora Therapeutics (DMRA) Form 3 show any stock transactions by Andrew Cheng?

No stock transactions are listed. The Form 3 for Andrew Cheng contains no reported purchases, sales, or derivative exercises, serving only as an initial ownership reporting statement at this time.

What role does Andrew Cheng hold at Damora Therapeutics (DMRA)?

Andrew Cheng is reported as a director of Damora Therapeutics, Inc. in the Form 3. This status makes him a reporting person subject to SEC beneficial ownership disclosure rules.

What is the significance of the Power of Attorney in the DMRA Form 3?

The remarks reference an Exhibit 24 - Power of Attorney, which typically authorizes designated individuals to sign and submit SEC ownership reports on behalf of Andrew Cheng in connection with his reporting obligations.

Does the Damora Therapeutics (DMRA) Form 3 mention a Rule 10b5-1 trading plan?

The Form 3 shows the Rule 10b5-1 checkbox as not indicated for Andrew Cheng. With no transactions reported, there is no disclosure of trades made under a 10b5-1 trading plan in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/13/2026 - 04:55 PM Accepted by SEC EDGAR 08/13/2026 - 04:55 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cheng Andrew

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.

221 CRESCENT ST., BLDG 23, STE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/12/2026

3. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Garrett Winslow	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)